Respon Klinis Neoadjuvant Chemotherapy Anthracyclines dan Taxane pada Locally Advanced Breast Cancer di RSUP H. Adam Malik Tahun 2020-2022

Abstract

Introduction: This study evaluates the clinical response to NAC in LABC patients treated at RSUP H. Adam Malik Medan between 2020 and 2022. Methods: This cross-sectional observational study at RSUP Haji Adam Malik Medan retrospectively analyzed breast cancer patients (2020–2022) undergoing neoadjuvant chemotherapy. Data on demographics, clinical variables, and treatment responses were extracted from medical records. Ethical approval was obtained, sample size calculated for adequate power, and statistical analyses performed using SPSS to evaluate chemotherapy efficacy. Results: This study included 50 breast cancer patients, predominantly females over 40 years (90%), with an average age of 49.8 years. The main histopathological type was Invasive Ductal Carcinoma (70%), and Luminal A was the most common molecular subtype (40%). Most patients were diagnosed at stage IIIB (84%) and had Grade 2 tumors (60%). Among 19 patients receiving chemotherapy, the Doxorubicin-Paclitaxel regimen was most common, with all showing partial response, indicating effective treatment outcomes. There is a significant difference in response distributions across the regimens (P<0.05). Conclusion:The findings suggests a significant partial clinical response following neoadjuvant chemotherapy with anthracyclines and taxane. Keywords: Neoadjuvant Chemotherapy (NAC), Locally Advanced Breast Cancer (LABC), Clinical Response